Mohammad Amjad Kamal is Distinguished Adjunct Professor at King Fahd Medical Research Center, King Abdulaziz University, Saudi Arabia. Professor Kamal’s overall biochemical research output has culminated in more than 600 publications in journals of international repute and 61 abstracts in international conferences. His research was pivotal in supporting the development of the novel anti-Alzheimer agents from the laboratory to the clinic via collaboration with Dr Nigel H. Greig (United States). He migrated to Australia in 1998 and was awarded a prestigious U2000 Postdoctoral Fellowship in 2000 by the University of Sydney, School of Molecular and Microbial Biosciences. Arun Kumar Singh earned his M. Pharm in Pharmaceutics from Galgotias University and currently serves as an Assistant Professor at the Amity Institute of Pharmacy, Amity University, Greater Noida. With over a decade of experience teaching pharmacology-related courses, Professor Singh has cultivated a diverse range of research interests, including nano-formulation, blockchain, IoT, machine learning, cancer, artificial intelligence, big data, and neuroscience. He has authored 5 book chapters, edited multiple books with notable international publishers, and has published 24 review papers, including two in the prestigious Biochimica et Biophysica Acta (BBA) – Reviews on Cancer. Renowned for his research acumen, innovative thinking, leadership, and positive outlook, Professor Singh's dedication and hard work have distinguished him as a leading figure in his field.Dr. Hitesh Chopra, PhD currently at Saveetha School of Engineering is working in primarily area of interest includes nanoformulations, natural polymers, cancer, and wound healing and metabolic disorders. He has authored several papers in high-repute journals with total impact factor more than 1000 Arya Rai, MPharm, is affiliated with the Department of Pharmacy, Chitkara College of Pharmacy. Her areas of interest include nanoformulation, cocrystal, blockchain, IoT, machine learning, cancer, artificial intelligence. She has two books’ chapters with different publishers. She has also published several artiles and 2 chapters in high impact factors journals.

• 1. A Brief Introduction of Cancer and nanocarriers2. Cancer therapies using nanocarriers with responsive mechanisms3. Signal-responsive nanocarriers for drug administration in cancer treatment4. Stimuli-Responsive Polymeric Nanoplatforms for Cancer Therapy5. An innovative approach to cancer treatment using stimuli-responsive nanoarchitecture for pharmaceutical delivery6. Anticancer therapy using nanoparticles that respond to stimuli in the tumor microenvironment7. Smart Nanocarriers Based on DNA and Stimuli for Cancer Diagnosis and Treatment: Potential Applications and Barriers8. Polymeric nanocarriers as stimuli-responsive cancer treatments: Emerging drug delivery technologies9. Tumor microenvironment modulation by stimuli-responsive polymeric nanomedicines based on gene medication delivery for enhanced cancer treatment10. Nanocarriers with stimuli-responsive properties for targeted gene delivery in cancer therapy.11. Genome editing for cancer therapy using a nanotechnology-based CRISPR/Cas9 delivery system12. Therapeutically-Inspired Stimuli-Responsive Nanoparticles for Customized Drug Release in Cancer13. Stimuli-Responsive Nanoparticles for Enhanced Cancer Immunotherapy via Controlled Drug Delivery14. Targeted delivery of cancer therapies using multifunctional and stimuli-responsive nanocarriers15. Stimuli-Responsive Anti-Tumor Therapy Using bio-derived materials Based Nanoparticles16. Developments and challenges in the targeted delivery of stimuli-responsive drugs for cancer treatments17. Application of Artificial Intelligence in Stimuli responsive-Nano-drug Targeting for Cancer Treatment18. Application of Artificial Intelligence in Stimuli responsive-Nano-drug Targeting for Theranostics

Mohammad Amjad Kamal is Distinguished Adjunct Professor at King Fahd Medical Research Center, King Abdulaziz University, Saudi Arabia. Professor Kamal’s overall biochemical research output has culminated in more than 600 publications in journals of international repute and 61 abstracts in international conferences. His research was pivotal in supporting the development of the novel anti-Alzheimer agents from the laboratory to the clinic via collaboration with Dr Nigel H. Greig (United States). He migrated to Australia in 1998 and was awarded a prestigious U2000 Postdoctoral Fellowship in 2000 by the University of Sydney, School of Molecular and Microbial Biosciences. Arun Kumar Singh earned his M. Pharm in Pharmaceutics from Galgotias University and currently serves as an Assistant Professor at the Amity Institute of Pharmacy, Amity University, Greater Noida. With over a decade of experience teaching pharmacology-related courses, Professor Singh has cultivated a diverse range of research interests, including nano-formulation, blockchain, IoT, machine learning, cancer, artificial intelligence, big data, and neuroscience. He has authored 5 book chapters, edited multiple books with notable international publishers, and has published 24 review papers, including two in the prestigious Biochimica et Biophysica Acta (BBA) – Reviews on Cancer. Renowned for his research acumen, innovative thinking, leadership, and positive outlook, Professor Singh's dedication and hard work have distinguished him as a leading figure in his field.Dr. Hitesh Chopra, PhD currently at Saveetha School of Engineering is working in primarily area of interest includes nanoformulations, natural polymers, cancer, and wound healing and metabolic disorders. He has authored several papers in high-repute journals with total impact factor more than 1000 Arya Rai, MPharm, is affiliated with the Department of Pharmacy, Chitkara College of Pharmacy. Her areas of interest include nanoformulation, cocrystal, blockchain, IoT, machine learning, cancer, artificial intelligence. She has two books’ chapters with different publishers. She has also published several artiles and 2 chapters in high impact factors journals.

• 1. A Brief Introduction of Cancer and nanocarriers2. Cancer therapies using nanocarriers with responsive mechanisms3. Signal-responsive nanocarriers for drug administration in cancer treatment4. Stimuli-Responsive Polymeric Nanoplatforms for Cancer Therapy5. An innovative approach to cancer treatment using stimuli-responsive nanoarchitecture for pharmaceutical delivery6. Anticancer therapy using nanoparticles that respond to stimuli in the tumor microenvironment7. Smart Nanocarriers Based on DNA and Stimuli for Cancer Diagnosis and Treatment: Potential Applications and Barriers8. Polymeric nanocarriers as stimuli-responsive cancer treatments: Emerging drug delivery technologies9. Tumor microenvironment modulation by stimuli-responsive polymeric nanomedicines based on gene medication delivery for enhanced cancer treatment10. Nanocarriers with stimuli-responsive properties for targeted gene delivery in cancer therapy.11. Genome editing for cancer therapy using a nanotechnology-based CRISPR/Cas9 delivery system12. Therapeutically-Inspired Stimuli-Responsive Nanoparticles for Customized Drug Release in Cancer13. Stimuli-Responsive Nanoparticles for Enhanced Cancer Immunotherapy via Controlled Drug Delivery14. Targeted delivery of cancer therapies using multifunctional and stimuli-responsive nanocarriers15. Stimuli-Responsive Anti-Tumor Therapy Using bio-derived materials Based Nanoparticles16. Developments and challenges in the targeted delivery of stimuli-responsive drugs for cancer treatments17. Application of Artificial Intelligence in Stimuli responsive-Nano-drug Targeting for Cancer Treatment18. Application of Artificial Intelligence in Stimuli responsive-Nano-drug Targeting for Theranostics

Mohammad Amjad Kamal is Distinguished Adjunct Professor at King Fahd Medical Research Center, King Abdulaziz University, Saudi Arabia. Professor Kamal’s overall biochemical research output has culminated in more than 600 publications in journals of international repute and 61 abstracts in international conferences. His research was pivotal in supporting the development of the novel anti-Alzheimer agents from the laboratory to the clinic via collaboration with Dr Nigel H. Greig (United States). He migrated to Australia in 1998 and was awarded a prestigious U2000 Postdoctoral Fellowship in 2000 by the University of Sydney, School of Molecular and Microbial Biosciences. Arun Kumar Singh earned his M. Pharm in Pharmaceutics from Galgotias University and currently serves as an Assistant Professor at the Amity Institute of Pharmacy, Amity University, Greater Noida. With over a decade of experience teaching pharmacology-related courses, Professor Singh has cultivated a diverse range of research interests, including nano-formulation, blockchain, IoT, machine learning, cancer, artificial intelligence, big data, and neuroscience. He has authored 5 book chapters, edited multiple books with notable international publishers, and has published 24 review papers, including two in the prestigious Biochimica et Biophysica Acta (BBA) – Reviews on Cancer. Renowned for his research acumen, innovative thinking, leadership, and positive outlook, Professor Singh's dedication and hard work have distinguished him as a leading figure in his field.Dr. Hitesh Chopra, PhD currently at Saveetha School of Engineering is working in primarily area of interest includes nanoformulations, natural polymers, cancer, and wound healing and metabolic disorders. He has authored several papers in high-repute journals with total impact factor more than 1000 Arya Rai, MPharm, is affiliated with the Department of Pharmacy, Chitkara College of Pharmacy. Her areas of interest include nanoformulation, cocrystal, blockchain, IoT, machine learning, cancer, artificial intelligence. She has two books’ chapters with different publishers. She has also published several artiles and 2 chapters in high impact factors journals.

• 1. A Brief Introduction of Cancer and nanocarriers2. Cancer therapies using nanocarriers with responsive mechanisms3. Signal-responsive nanocarriers for drug administration in cancer treatment4. Stimuli-Responsive Polymeric Nanoplatforms for Cancer Therapy5. An innovative approach to cancer treatment using stimuli-responsive nanoarchitecture for pharmaceutical delivery6. Anticancer therapy using nanoparticles that respond to stimuli in the tumor microenvironment7. Smart Nanocarriers Based on DNA and Stimuli for Cancer Diagnosis and Treatment: Potential Applications and Barriers8. Polymeric nanocarriers as stimuli-responsive cancer treatments: Emerging drug delivery technologies9. Tumor microenvironment modulation by stimuli-responsive polymeric nanomedicines based on gene medication delivery for enhanced cancer treatment10. Nanocarriers with stimuli-responsive properties for targeted gene delivery in cancer therapy.11. Genome editing for cancer therapy using a nanotechnology-based CRISPR/Cas9 delivery system12. Therapeutically-Inspired Stimuli-Responsive Nanoparticles for Customized Drug Release in Cancer13. Stimuli-Responsive Nanoparticles for Enhanced Cancer Immunotherapy via Controlled Drug Delivery14. Targeted delivery of cancer therapies using multifunctional and stimuli-responsive nanocarriers15. Stimuli-Responsive Anti-Tumor Therapy Using bio-derived materials Based Nanoparticles16. Developments and challenges in the targeted delivery of stimuli-responsive drugs for cancer treatments17. Application of Artificial Intelligence in Stimuli responsive-Nano-drug Targeting for Cancer Treatment18. Application of Artificial Intelligence in Stimuli responsive-Nano-drug Targeting for Theranostics